Zymeworks to Get $55M Upfront, Up to $813M, in Roche Licence Deal
Roche has agreed to license ZW209, an early-stage cancer drug from Vancouver-based Zymeworks, in a deal worth up to $813 million, according to Reuters. Zymeworks announced the global licence and collaboration agreement on Oct. 23, 2026.
What happened
Under the terms Zymeworks released, the company will receive:
- $55 million upfront from Roche.
- $40 million more when a Phase 1b trial of ZW209 begins.
- Up to $718 million in development, commercial and sales-based milestones.
- Tiered royalties on net sales, from high single digits to mid-teen percentages.
Roche gets exclusive global rights to ZW209. Zymeworks will keep running the Phase 1a trial, which tests the drug alone, in collaboration with Roche. Roche will pay for that study and then take charge of global development and sales.
The deal still has to clear the waiting period under the US Hart-Scott-Rodino antitrust law, along with other customary conditions and any required regulatory approvals.
ZW209 is a trispecific T cell engager. It is built to bind DLL3 on tumour cells while also binding CD3 and CD28 on T cells. Zymeworks says the way it binds T cells and engages CD28 only under certain conditions is designed to prevent unintended T cell activation.
The FDA has cleared an investigational new drug application for ZW209. Zymeworks says a global Phase 1 study has started. It will enrol adults with select advanced solid tumours, including small cell lung cancer and other neuroendocrine tumours that carry DLL3. Zymeworks CEO Kenneth Galbraith told Reuters he expects the first patient to enrol before the end of 2026.
Why it matters
Roche signed on before efficacy data were available, according to Reuters. Galbraith credited the company's trispecific T cell engager platform for that interest.
DLL3 is common on small cell lung cancer cells but rare in healthy tissue, according to a Reuters report carried by Medical Dialogues.
The structure also fits a plan Zymeworks has described. Its head of R&D, Adam Schayowitz, said the company partners selected assets so it can share development risk while keeping a stake in their success. Boris Zaïtra, Roche's head of corporate business development, said ZW209 complements Roche's ongoing efforts to develop new treatment options for people with lung cancer.
What it means for people in the industry
The upfront and near-term payments go to a biotech based in Vancouver. The announcement did not say whether the deal will add jobs or facilities in Canada or the US.
Things to watch include the deal closing, the first patient enrolled in the Phase 1 study and the start of the Phase 1b trial, which triggers the next payment. The announcement did not give a date for early safety or activity results.
Sources
- Zymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3, Zymeworks (press release filed with the SEC)
- Zymeworks licenses cancer therapy to Roche for up to $813m, BioXconomy
- Roche Inks USD 813 Mn Deal with Zymeworks for Experimental Lung Cancer Drug ZW209, Medical Dialogues
Check Your Supplement Interactions
Use our AI-powered checker to analyze supplement safety and interactions.
Open Interaction Checker →Comments (0)
This article is for informational purposes only and does not constitute medical or investment advice. It was written with AI assistance from the sources listed above. Check the original sources before relying on any detail.